Morepen Board proposed dividend after 23 years
Scores highest PAT of Rs. 118 crore in FY25
Scores highest PAT of Rs. 118 crore in FY25
The Q1 2025 also witnessed a successful launch of Allegra D
Investment demonstrates confidence in America’s commitment to science and innovation
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
Subscribe To Our Newsletter & Stay Updated